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Abstract
Background: A few studies focused on statin therapy as specific prophylactic measures of contrast-induced nephropathy
have been published with conflicting results. In this meta-analysis of randomized controlled trials, we aimed to assess the
effectiveness of shor-term high-dose statin treatment for the prevention of CIN and clinical outcomes and re-evaluate of the
potential benefits of statin therapy.
Methods: We searched PubMed, OVID, EMBASE, Web of science and the Cochrane Central Register of Controlled Trials
databases for randomized controlled trials comparing short-term high-dose statin treatment versus low-dose statin
treatment or placebo for preventing CIN. Our outcome measures were the risk of CIN within 2–5 days after contrast
administration and need for dialysis.
Results: Seven randomized controlled trials with a total of 1,399 patients were identified and analyzed. The overall results
based on fixed-effect model showed that the use of short-term high-dose statin treatment was associated with a significant
reduction in risk of CIN (RR=0.51, 95% CI 0.34–0.76, p=0.001; I
2=0%). The incidence of acute renal failure requiring dialysis
was not significant different after the use of statin (RR=0.33, 95% CI 0.05–2.10, p=0.24; I
2=0%). The use of statin was not
associated with a significant decrease in the plasma C-reactive protein level (SMD 20.64, 95% CI: 21.57 to 0.29, P=0.18,
I
2=97%).
Conclusions: Although this meta-analysis supports the use of statin to reduce the incidence of CIN, it must be considered in
the context of variable patient demographics. Only a limited recommendation can be made in favour of the use of statin
based on current data. Considering the limitations of included studies, a large, well designed trial that incorporates the
evaluation of clinically relevant outcomes in participants with different underlying risks of CIN is required to more
adequately assess the role for statin in CIN prevention.
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Introduction
Contrast-induced nephropathy (CIN), characterized by the
development of acute renal failure after exposure to radiocontrast,
is the third leading cause of hospital-acquired acute renal injury,
accounting for 11% of all cases [1]. It is defined as an increase in
baseline serum creatinine level of 25% or an absolute increase of
44 mmol/L (0.5 mg/dL). Although CIN is generally benign in
most instances, it is associated with lengthened hospital stays,
increased health care costs, and higher risk of death [2–4]. Several
strategies, including using iso-osmolar contrast, limiting the
amount of administered contrast media and volume expansion
have become well established methods for the prevention of CIN.
The pathophysiological mechanisms of CIN is not well known.
However, multiple studies have suggested that renal vasoconstric-
tion, oxidative stress, inflammation and direct tubular cell damage
by contrast media may play crucial important roles in the renal
injury process [5–8]. Statins, drugs primarily associated with low-
density lipoprotein cholesterol-lowering effects, have been shown
to possess pleiotropic effects that include enhancement of
endothelial nitric oxide production [9–11], anti-inflammatory
and antioxidative actions [12,13]. Therefore, statins are consid-
ered as promising candidate agents for the prevention of CIN.
A few studies focused on statin therapy as specific prophylactic
measures of CIN have been published with conflicting results [14–
22]. In this meta-analysis of randomized controlled trials (RCTs),
we aimed to assess the effectiveness of short-term high-dose statin
treatment for the prevention of CIN and clinical outcomes and re-
evaluate of the potential benefits of statin therapy.
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PLoS ONE | www.plosone.org 2 April 2012 | Volume 7 | Issue 4 | e34450Materials and Methods
Search strategy
The literature search was performed on PubMed (1966-
October 2011), OVID (1966 to October 2011), EMBASE (1966-
October 2011), Web of science (1986- October 2011) and the
Cochrane Central Register of Controlled Trials (1996 to October
2011). We derived three comprehensive search themes that were
then combined using the Boolean operator ‘‘AND’’. For the theme
‘‘contrast media’’, we used combinations of MeSH, entry terms
and text words: contrast, radiocontrast, contrast medium, contrast
media, contrast dye, radiographic contrast, radiocontrast media,
radiocontrast medium and contrast agent. For the theme ‘‘renal
insuficiency’’, we used: renal insufficiency, renal failure, diabetic
nephropathies, nephritis, nephropathy, nephrotoxic, (impair or
injury or damage or reduce) and (renal or kidney), contrast-
induced nephropathy and contrast-associated nephropathy. For
the theme ‘‘statin’’, statin, atorvastatin, rosuvastatin, cerivastatin,
simvastatin, pravastatin, lovastatin, Hydroxymethylglutar-
yl(HMG)-CoA reductase inhibitors and HMG-CoA reductase
inhibitors were used. Appendix S1 shows the detailed search
method. We did not restrict by language or type of article. To
identify other relevant studies, we manually scanned reference lists
from identified trials and review articles, and we also searched
conference proceedings. We requested original data by directly
contacting authors.
Study selection
We included studies when the following criteria were met: (1)
randomized, controlled trials assessing preventive strategies for
CIN; (2) the intervention was high-dose statin (defined as a daily
dose of 80 mg or 40 mg) versus low-dose statin treatment (defined
as a daily dose of 20 mg or 10 mg) or placebo. Studies that
incorporated NAC were included only if both arms were
administered NAC; (3) studies reported the incidence of
contrast-induced nephropathy in both arms. We did not restrict
eligibility according to kidney function. The primary outcome
measure was the development of contrast-induced nephropathy,
defined as an increase in baseline serum creatinine level of 25% or
an absolute increase of 44 mmol/L (0.5 mg/dL) within 2 to 5 days
after the exposure to contrast medium. Secondary outcome
measures were need for dislysis, in-hospital mortality and length
of hospital stay.
Data extraction and quality assessment
Data were collected independently by 2 reviewers. Extracted
data included patient characteristics (mean age, diabetes status,
mean baseline creatinine level and postprocedural change in C-
reactive protein level); inclusion criteria; type and dose of contrast
media; protocol for the treatment of statins; periprocedural
hydration protocol and specific definition of CIN. Quality
assessment was judged on concealment of treatment allocation;
similarity of both groups at baseline regarding prognostic factors;
eligibility criteria; blinding of outcome assessors, care providers,
and patients; completeness of follow-up; and intention-to-treat
analysis [23]. We quantified study quality by using the Jadad score
[24]. A third reviewer adjudicated any disagreement about
extracted data. Then data were checked and entered into the
Review Manager (Version 5.0. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2008) database
for further analysis.
Figure 1. Study selection diagram.
doi:10.1371/journal.pone.0034450.g001
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Author,
year
Mean
age,y
Diabetic
patients,%
Mean
baseline sCr
level,mmol/L
(mg/dL)
Postprocedural changes
in CRP levels,
mg/L (Mean±SD)
Definition
of CIN Events,n
Statin Control Statin Control Statin Control Statin Control Statin Control
Sang-Ho Jo
et al,2008
65 66 28.2% 23.6% 114(1.286) 110(1.248) 1.2561.25 1.2761.79 Increase of
Scr.0.5 mg/dL or
.25% within
48 hours
34
Anna Toso
et al,2009
75 76 20% 22% 106(1.2) 104(1.18) NS NS Increase of
Scr$0.5 mg/dl
within 5 days.
15 16
Xinwei
et al,2009
65 66 20% 22% 72(0.82) 73(0.83) 1.960.5 3.461.2 Increase of
Scr.0.5 mg/dL or
.25% within
48 hours
61 8
Zhou Xia
et al,2009
60 61 22% 18% 92(1.04) 95(1.08) NS NS Increase of
Scr.0.5 mg/dL or
.25% within
72 hours
03
Sadik Acikel
et al,2010
59 61 23.8% 25.0% 74(0.84) 75(0.85) NS NS Increase of
Scr.0.5 mg/dL
within 48 hours
01
Hakan Ozhan
et al,2010
54 55 15.00% 17.14% 77.8(0.88) 77.8(0.88) NS NS Increase of
Scr.0.5 mg/dL or
.25% within
48 hours
27
Giuseppe Patti
et al,2011
65 66 30% 25% 92(1.04) 92(1.04) 8.4610.5 13.1620.8 Increase of
Scr.0.5 mg/dL or
.25% within
48 hours
61 6
Statin=statin-treated group (high-dose);Control=control group (low-dose or non-statin);CAG=coronary angiography;PCI=percutaneous coronary
intervention;CrCl=creatinine clearance;Scr=serum creatinine;CRP=C-reactive protein;eGFR=estimated glomerular filtration rate;NAC=N-acetylcysteine;NS=0.9%
sodium chloride; NS=not specified or available.
doi:10.1371/journal.pone.0034450.t002
Table 3. Quality of included RCTs.
Author,
Year
Jadad
Score
Allocation
Concealment
Similarity of
Baseline
Characteristics
Eligibility
Criteria Blinding
Completeness of
Follow-up
Intention-to-
Treat
Analysis
Outcome
Assessor
Care
Provider Patient
Sang-Ho Jo
et al,2008
5 YES YES YES NS YES YES YES YES
Anna Toso
et al,2009
5 YES YES YES NS YES YES YES YES
Xinwei
et al,2009
3 YES YES YES NO NO NO YES NS
Zhou Xia
et al,2009
3 N SY E S Y E S N SN SN SY E S N S
Sadik Acikel
et al,2010
1 NS NO YES NO NO NO YES NS
Hakan Ozhan
et al,2010
2 N SY E S Y E S N ON ON OY E S N S
Giuseppe
Patti
et al,2011
5 YES YES YES YES YES YES YES YES
NS=not specified or available.
doi:10.1371/journal.pone.0034450.t003
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Dichotomous data (contrast-induced nephropathy and need for
dialysis) were analyzed using the risk ratio (RR) measure and its
95% confidence interval (CI). Moreover, heterogeneity across
trials was evaluated with I
2 statistic, which defined as I
2.50%. If
heterogeneity existed, a random-effect model was used to assess
the overall estimate. Otherwise, a fixed-effect model was chosen.
We assessed for potential publication bias by using Begg funnel
plots of the natural log of the relative risk versus its standard error
[25]. To further detect and evaluate clinically significant
heterogeneity, we also a priori decided to perform several
subgroup analyses to identify potential differences in treatment
across the trials. Subgroup analysis was conducted based on renal
function in participants at baseline (with or without renal
impairment), the control group property (low dose of statin or
control), the addition of NAC (with or without NAC), and Jadad
study quality score (Jadad.3 or Jadad#3). All tests were two-
tailed and a P value less than 0.05 was regarded as significant in
this meta-analysis.
Results
Selected studies and characteristics
We identified 322 potentially relevant citations from the initial
literature search. After independently reviewing the title and
abstract of all potential articles, 34 articles were considered of
interest and reviewed in full-text. Of these, 27 were excluded from
the meta-analysis (review articles, retrospective studies, prospective
obervational studies, irrelevant to our aim). Although the study
carried out by Acikel Sadik et al [20] did not provide data on the
incidence of CIN, we requested it by directly contacting the
author. Therefore, seven randomized controlled studies with a
total of 1,399 patients with undergoing radiocontrast-related
procedures were identified and analyzed [16–22]. Our search
strategy is outlined in Figure 1.
Table 1 and table 2 summarizes the characteristics of the
included studies. All of them had been reported since 2008. 693
subjects were assigned to short-term high-dose statin treatment
group and 706 subjects were assigned to short-term low-dose or
non-statin treatment group. The proportion of patients lost to
follow-up was less than 5% in all studies. CIN was defined
Figure 2. Forest plot of risk ratios and 95% confidence intervals (CI) for the incidence of contrast induced nephropathy among
patients assigned to statin therapy versus control.
doi:10.1371/journal.pone.0034450.g002
Figure 3. Funnel plot with 95% confidence intervals (CI) to assess for evidence of publication bias.
doi:10.1371/journal.pone.0034450.g003
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e34450differently among the included studies. Six studies [16,17,19–22]
used an increase in serum creatinine of .0.5 mg/dL or .25%
from baseline within 48–72 h after radiocontrast exposure as their
definition, whereas the other study [18] regarded an absolute
increase in serum creatinine of .0.5 mg/dl within 5 days as their
primary definition of CIN. Two studies [17,18] involved patients
with creatinine clearance rate less than 60 ml/min; four studies
[16,20–22] enrolled patients with creatinine clearance rate or
estimated glomerular filtration rate.60 ml/min and there was no
restriction according to renal function but patients with creatinine
level .3 mg/dl were excluded in the study by Patti G et al [19].
All studies evaluated patients undergoing coronary angiography or
Figure 4. Forest plot of risk ratios and 95% confidence intervals (CI) for the incidence of CIN among patients assigned to short-term
high-dose statin treatment versus low-dose or non-statin.
doi:10.1371/journal.pone.0034450.g004
Figure 5. Forest plot of risk ratios and 95% confidence intervals (CI) for the incidence of CIN among patients assigned to statin
therapy versus control with NAC using or not.
doi:10.1371/journal.pone.0034450.g005
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tion (PCI). All of the patients received low-osmolar or iso-osmolar
contrast media and median contrast volume ranged from 93 ml to
240 ml. Periprocedural hydration was used in every one, except
the patients without pre-existing renal failure in the study by Patti
G et al [19]. Five studies [16,18–20,22] used atorvastatin and
simvastatin was used in the other two studies [17,21]. The
duration of statin treatment ranged from 3 to .7 days and the
total dose ranged from 140 mg to .460 mg in the high-dose statin
treatment group. Two of the included studies [16,18] also used
Figure 6. Forest plot of risk ratios and 95% confidence intervals (CI) for the incidence of CIN among patients assigned to statin
therapy versus control according to renal function.
doi:10.1371/journal.pone.0034450.g006
Figure 7. Forest plot of risk ratios and 95% confidence intervals (CI) for the incidence of CIN among patients assigned to statin
therapy versus control according to Jadad score.
doi:10.1371/journal.pone.0034450.g007
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arms, started the day before the procedure. Allocation conceal-
ment and blinding were used in three studies [17–19] and the
quality characteristics of the studies were shown in table 3.
Effects of statin treatment on clinical outcomes
The overall results based on fixed-effect model showed that the
use of short-term high-dose statin treatment was associated with a
significant reduction in risk of CIN (RR=0.51, 95% CI 0.34–
0.76, p=0.001; I
2=0%; Figure 2). The incidence of acute renal
failure requiring dialysis was very low and was not significant
different after the use of statin (3 studies [17–19], RR=0.33, 95%
CI 0.05–2.10, p=0.24; I
2=0%).
In-hospital mortality was observed in only one patient who died
from acute heart failure aggravated by major bleeding in these
seven studies [18]. Although the study carried out by Zhou Xia et
al [22] reported incidence of cardiovascular event in short-term
high-dose treatment group (5/50) and low-dose group (2/50), it
didn’t give any details. The total length of hospital stay were
reported only in two studies. There was no difference between
statin-treated group and control group in length of hospital stay in
the study [17] by Jo SH et al. However, length of stay after
intervention was shorter in patients randomized to atorvastatin
(2.960.9 vs 3.260.8 days, P=0.007) in the other study [19].
Figure 3 demonstrates that there was no evidence to suggest
publication bias according to the relative symmetry in the Begg
funnel plot.
Postprocedural changes in C-reactive protein (CRP) levels were
analyzed in three trials [17,19,21]. The use of statin was not
associated with a significant decrease in the plasma CRP level
(SMD 20.64, 95% CI: 21.57 to 0.29, P =0.18, I
2=97%).
Subgroup analysis
Classified according to low-dose statin-treated or not in control
group, studies [16–20] comparing short-term high-dose statin
treatment with non-statin treatment showed a significant protec-
tive trend toward decreased incidence of CIN (RR=0.61, 95%CI
0.38–0.97, P=0.04; Figure 4) and the same effect was seen in
other two studies [21,22] which compared short-term high-dose
with low-dose statin treament (RR=0.31, 95%CI 0.13–0.72,
P=0.006).
In all five studies in which statin was compared with control
without the addition of NAC, the risk of CIN was significantly
decreased (RR=0.38, 95%CI 0.22–0.65, P=0.0006; Figure 5). In
contrast, the risk of CIN did not significantly differ in the two
studies in which statin plus NAC versus NAC only (RR=0.76,
95%CI 0.42–1.39, P=0.38).
In studies that included patients without renal impairment at
baseline (creatinine clearance rate or estimated glomerular
filtration rate.60 ml/min), RR was 0.29 (95%CI 0.15–0.57,
P=0.0003; Figure 6). A reduced risk of CIN was not found in
studies that included patients with pre-existing renal impairment
(creatinine clearance rate #60 ml/min). RR for CIN associated
with the use of statin was 0.79 (95%CI 0.47–1.32, P=0.37).
Classified according to the Jadad score .3 or not, studies whose
Jadad score#3 showed a significant reduction of CIN (RR=0.31,
95%CI 0.15–0.65, P=0.002; Figure 7). However, the risk of CIN
did not significantly differ in the studies whose Jadad score.3
(RR=0.67, 95%CI 0.41–1.10, P=0.11).
Discussion
In the past two decades, although hydration has been well
recognized and widely performed to prevent the CIN, the
incidence of CIN did not decrease. So the efficacy of many other
interventions are still under testing. From 2004 to 2011, a few
studies focused on using statin as a specific prophylactic measure of
CIN prevention have been published. In this meta-analysis of 7
randomized controlled trials (RCTs), we found that statin could
significantly reduce the risk of CIN without decreasing the
incidence of death or need for dialysis. However, there was
marked clinical heterogeneity among these studies, indicating the
need for a large definitive RCT.
In addition to their intended impact on blood cholesterol levels,
statins have been found to have multiple nonlipid-lowering effects,
which include enhancement of endothelial nitric oxide production
[9–11], anti-inflammatory and antioxidative actions [12,13].
Given their pleiotropic effects, statins could decrease acute renal
injury after iodinated contrast administration through two major
pathways. Firstly, statins may modulate the kidney hypoperfusion
after contrast administration by downregulation of angiotensin
receptors and decreased synthesis of endothelin-1 [26,27].
Secondly, toxic damage on the tubular cells by oxygen-free
radicals and proinflammatory cytokines may be decreased by anti-
inflammatory effects of statins that inhibit tissue factor expression
by macrophages and prevent the activation of nuclear factor-kB
[28]. Moreover, its nonlipid-lowering effect could be demonstrated
within a few hours after statin therapy initiation [29,30]. Although
many clinical trials [31,32] have shown that high-dose statins
provide more clinical benefits, such as atorvastatin 80 mg can
further reduce vascular risks compared with low-dose statin
therapy, the threshold of statins to reduce the risks of CIN
remains unknown. In this meta-analysis, all of the included trials
were short-term high-dose statin therapy, two of which compared
two different doses of statin in preventing CIN. We found that
high-dose statin therapy significantly lowered the incident of CIN
compared with low-dose statin therapy. These results were
consistent with the previous studies that high-dose statin has been
shown to be more potent to suppress platelet activity and
inflammatory chemokines than low-dose statin therapy [33]
.
The results of this meta-analysis are not in line with research
from Zhang T et al [34], Zhang L et al [35] and Pappy R et al [36]
which showed non-statistically significant reduction in the
incidence of CIN with statin treatment from the pooled estimate
for the randomized trials. In fact, Zhang T et al [34] and Pappy R
et al [36] included both randomized and non-randomized trials in
their meta-analysis, while the latter might lead to potential bias
because it was impossible to completely remove interference of
unknown confounding factors. The meta-analysis by Zhang L et al
[35] involved only 4 RCTs, which included an abstract that
overlapped with participants included in a separate study by the
same author. Therefore, to avoid including any individual
participant more than once, abstract by the same author was
excluded in our meta-analysis [37]. Moreover, all of above three
meta-analysis did not include two large scale studies [19,20]
published in recent days.
Although the main conclusion in our meta-analysis was similar
to that in the recent meta-analysis [38,39], these similar results
shall be treated with cautious interpretation. First, in our meta-
analysis, we found that statin was able to prevent CIN only in
studies with lower quality, especially those which did not use of
blinding, but not effective in high quality studies. This indicated
that the results from the meta-analysis could not definite the effects
of statins in preventing CIN. Second, pre-existing renal dysfunc-
tion was known to be an independent predictor of CIN that
occured in up to 15% of patients with chronic kidney disease
(CKD). However, subgroup analysis in risk group for CIN also
weakened our findings. The studies that included patients with
Statin Prevents Contrast-Induced Nephropathy
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Multiple nonreversible pathogenetic mechanisms involved in
advanced renal failure may attenuate the response for statins,
especially for their vasodilatation and anti-inflammatory effects. In
addition, although a higher serum level was expected in CKD
patients, local drug concentration still might be compromised due
to renal scar and structural impairment. So the safety, pharma-
cokinetics and permeability of various statins in CKD patients
should be well evaluated in future studies. Third, N-acetylcysteine,
a thiol-containing antioxidant, was a promising agent to prevent
contrast induced nephropathy because of its antioxidative and
haemodynamic effects in the renal medulla and its general organ-
protective effects described in several ischaemia-reperfusion
models [40]. In the subgroup analysis of statin plus NAC versus
NAC only, the difference were not significant. This could be
attributed to that statin and NAC might decrease CIN occurrence
through the similar pathways, such as scavenging oxygen free
radicals produced after contrast exposure; therefore, the second
agent could not exert addictive renal protection if NAC offered full
protection available through antioxidants.
There are several potential limitations in this meta-analysis.
Firstly, although all included studies reported the incidence of
CIN, few trials designed to investigate the effect of statins on hard
clinical outcomes such as acute renal failure requiring dialysis,
length of hospital stay and in-hospital mortality. Secondly, we did
not have access to patient-level data to determine whether the risk
factors (eg, diabetes and age) could influence the effect of short-
term high-dose statin treatment on the risk of contrast-induced
nephropathy. Finally, studies included in this meta-analysis
analyzed the efficacy of statin with different type of statins for
varied periods of time. It is possible that dose, duration and type of
statin may have differential effect in prevention of CIN. An
accepted uniform statin protocol would be helpful in both the
clinical and research arenas.
In conclusion, although this meta-analysis supports the use of
statin to reduce the incidence of CIN, this result must be
considered in the context of variable patient demographics. Only a
limited recommendation can be made in favour of the use of statin
based on current data. Considering the limitations of included
studies, a large, well designed trial that incorporates the evaluation
of clinically relevant outcomes in participants with different
underlying risks of CIN is required to more adequately assess
the role for statin in CIN prevention.
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